Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Return on Sales (2023 - 2025)

NewAmsterdam Pharma's Return on Sales history spans 3 years, with the latest figure at 2221.66% for Q4 2025.

  • For Q4 2025, Return on Sales rose 222887.0% year-over-year to 2221.66%; the TTM value through Dec 2025 reached 2.57%, up 273.0%, while the annual FY2025 figure was 2.57%, 273.0% up from the prior year.
  • Return on Sales for Q4 2025 was 2221.66% at NewAmsterdam Pharma, up from 206.91% in the prior quarter.
  • Across five years, Return on Sales topped out at 2221.66% in Q4 2025 and bottomed at 206.91% in Q3 2025.
  • The 3-year median for Return on Sales is 10.25% (2025), against an average of 157.53%.
  • The largest YoY upside for Return on Sales was 222887bps in 2025 against a maximum downside of -20634bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 24.77% in 2023, then plummeted by -129bps to 7.22% in 2024, then soared by 30883bps to 2221.66% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Return on Sales are 2221.66% (Q4 2025), 206.91% (Q3 2025), and 0.91% (Q2 2025).